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MeloxicamAbstract The purpose of this study was to investigate the anti-inﬂammatory, analgesic, antipyretic
and antiulcer properties of somatostatin analogue octreotide (10 and 100 lg/kg) and its inﬂuence on
the effect of NSAID meloxicam (1 and 2 mg/kg) in rats. Carrageenan-induced rat paw oedema was
used as an acute anti-inﬂammatory model as well as adjuvant-induced arthritis as a chronic model.
Hot plate test on rats and acetic acid (0.6%) writhing test were used as acute analgesic models while
the plantar test using an infrared beam directed to the paw of arthritic rats was used as a chronic
analgesic model. Antipyretic effect was evaluated using Brewer’s yeast (44%) induced hyperthermia
in rats while pylorus ligation was used as a model to evaluate the ulcerogenic effects. Meloxicam,
octreotide and their combinations administered subcutaneously showed anti-inﬂammatory effects
in both acute and chronic models. Only the high doses of meloxicam and octreotide showed signif-
icant analgesic effect in the hot plate test, while all doses showed signiﬁcant analgesic effects in the
acetic acid-induced writhing test and in the plantar test. In yeast-induced hyperthermia, only
meloxicam has an antipyretic effect. Meloxicam resulted in profound gastric lesions and exerted del-
eterious effects on the gastric mucosa in pyloric-ligated rats. Octreotide did not cause any harmful
effect on the gastric mucosa, besides; octreotide attenuated the harmful ulcerogenic effects of
124 S. Abdul Wanees El-Awdan et al.meloxicam when administered in combination with it. Both meloxicam and octreotide and their
combination signiﬁcantly decreased the malondialdehyde (MDA) content in the arthritic rats indi-
cating their antioxidant effects.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Inﬂammation is a sequence of defensive reactions of the vascu-
larized tissues to the pathogenic insult of another origin. Rheu-
matoid arthritis (RA) is a chronic, systemic, relapsing,
debilitating inﬂammatory autoimmune disorder that presents
as a symmetric polyarthritis associated with swelling and pain
in multiple joints (Sweeney and Firestein, 2004).
Most classical nonsteroidal anti-inﬂammatory drugs (NSA-
IDs) including aspirin, indomethacin or ibuprofen, show little
speciﬁcity of inhibition towards COX isforms (Vane and Bot-
ting, 1995; Lora et al., 1997). Studies with compounds such as
meloxicam (Dequeker et al., 1998), nimesulide (Lapeyre-
Mestre et al., 2011), celecoxib (Louder et al., 2011) have
demonstrated that selective COX-2 inhibitors retain the anti-
inﬂammatory effects characteristic of NSAIDs with a marked
increase in gastrointestinal tolerability as compared to classical
non selective ones. Meloxicam is a member of the enolic acid
group of NSAIDs. It is a COX-2 preferential with less gastro-
intestinal toxicity than nonselective NSAIDs (Beubler, 2003).
Somatostain is a neuropeptide that is widely distributed
in the stomach, the gastrointestinal tract and the pancreas.
Various actions of somatostatin are mediated through spe-
ciﬁc membrane receptors, which have been demonstrated
in various regions of the brain. Furthermore, receptors
are identiﬁed in the anterior pituitary, endocrine and exo-
crine pancreas, the mucosa of the gastrointestinal tract, as
well as in cells of the immune system (Sreenivasan et al.,
2011).
Somatostatin functions as a neurotransmitter with gener-
ally inhibitory actions in many regions of the central nervous
system. Synthetic, metabolically stable analogues have been
developed for clinical use. However, only two of these, namely
octreotide and lanreotide, were introduced for routine thera-
pies in humans (Strosberg et al., 2011).
Somatostatin plays an important role in inﬂammation. The
expression of somatostatin has been found in the inﬂammatory
foci, and this neurohormone is considered to be a local anti-
inﬂammatory factor (Ohno et al., 1990). Activation of periphe-
ral somatostatin receptors reduces both the inﬂammatory pain
and the activity of sensitized receptors (Carlton et al., 2001).
It has been shown that somatostatin may restrict the
inﬂammatory process in several ways: It down modulates a
number of immune functions such as lymphocyte prolifera-
tion, immunoglobulin production and the release of the proin-
ﬂammatory cytokines such as interferon-c (INF-c) (Ten
Bokum et al., 2000). It acts antagonistically to substance P,
the main neuroendocrine proinﬂammatory mediator (Ten
Bokum et al., 2000). It also inhibits plasma and leucocyte
extravasation (Wiedermann et al., 1993) and induces vasocon-
striction and inhibits angiogenesis (Reubi et al., 1994;
Heppelmann and Pawlak, 1997).
Taken together, the aim of the present work is to study the
possible modulation of the pharmacological properties of
meloxicam by the combined therapy with octreotide.2. Material and methods
2.1. Animals
Adult male albino Sprague–Dawley rats weighing 130–150 g
and adult male Swiss albino mice weighing 20–25 g were used
in the present study; they were obtained from the animal house
colony in the National Research Center (Giza, Egypt).
2.2. Drugs
1. Octreotide acetate was obtained from Novartis Pharma
(Cairo, Egypt), and the used ampoule was 100 lg/ml.
Two doses were used: 10 and 100 lg/kg.
2. Meloxicam was generously gifted fromAmoun Pharmaceutical
Company (Cairo, Egypt) and used in two doses: 1 and 2 mg/kg.3. Methods
3.1. The carrageenan-induced rat paw oedema
Paw oedema was induced by subplantar injection of 100 ll of
1% sterile carrageenan in saline into the right hind paw (Win-
ter et al., 1962). The rats received vehicle or drugs 1 h before
carrageenan injection. The hind paw volume was measured
immediately before carrageenan injection and at selected times
thereafter by water displacement method using 7410, plythes-
mometer, Ugo Basile, Comerio, Italy (Fig. VI) (Chattopadhy-
ay et al., 2002).
3.2. The adjuvant-induced arthritis
Adjuvant arthritis was induced by subplantar injection of 0.1 ml
Freund’s complete adjuvant (FCA) in the right hind paw (Pear-
son, 1956). Paw volume was duplicately measured just prior to
adjuvant injection and at intervals of three days for 30 days after
adjuvant injection using a water displacement plethysmometer
and the mean values were recorded (Chakraborty et al., 2004).
3.3. The hot plate test
For three consecutive days preceding the experiment, rats were
adapted on the hot plate by placing them on a plate maintained
at room temperature for 15 min each day. Each animal was then
placed gently onto a 50 C hot plate to perform the test. Latency
to exhibit nociceptive responses, such as licking paws or jumping
off the hot plate was determined 30, 60, 120 min after administra-
tion of test substances or the saline (Laviola and Alleva, 1990).
3.4. The writhing test
The vehicle and the drugs were administered subcutaneously
30 min before the intraperitoneal injection of 0.6% acetic acid
in distilled water (10 ml/kg). The stretching reaction was
Table 1 Effect of meloxicam, octreotide and their combinations on the carrageenan-induced paw oedema in rats.
Groups Oedema volume (ml)
0 h 1 h 2 h 3 h 4 h
Control 0.36 ± 0.012 0.55 ± 0.011* 0.59 ± 0.015* 0.62 ± 0.012* 0.64 ± 0.011*
Mel. 0.5 mg/kg 0.34 ± 0.009 0.43 ± 0.017*,@ 0.47 ± 0.015*,@ 0.50 ± 0.014*,@ 0.52 ± 0.015*,@
Mel. 1 mg/kg 0.36 ± 0.026 0.45 ± 0.014*,@ 0.47 ± 0.015*,@ 0.50 ± 0.009*,@ 0.52 ± 0.009*,@
Mel. 2 mg/kg 0.34 ± 0.007 0.41 ± 0.008*,@ 0.44 ± 0.011*,@ 0.47 ± 0.012*,@ 0.49 ± 0.011*,@
Oct. 10 lg/kg 0.31 ± 0.013 0.43*@ ± 0.011 0.49*@ ± 0.010 0.52*@ ± 0.008 0.53 ± 0.020 *@
Oct. 25 lg/kg 0.34 ± 0.006 0.44*@ ± 0.008 0.50*@ ± 0.013 0.53*@ ± 0.011 0.55 ± 0.010 *@
Oct. 100 lg/kg 0.33 ± 0.005 0.43*@ ± 0.009 0.48*@ ± 0.012 0.51*@ ± 0.010 0.52 ± 0.010 *@
Mel. 1 mg/kg + Oct 10 lg/kg 0.35 ± 0.005 0.45 ± 0.009*,@ 0.47 ± 0.007*,@ 0.50 ± 0.007*,@ 0.51 ± 0.009*,@
Mel. 1 mg/kg + Oct. 100 lg/kg 0.33 ± 0.006 0.39 ± 0.005*,@ 0.42 ± 0.009*,@ 0.46 ± 0.011*,@ 0.49 ± 0.011*,@
The data represent the mean ± standard error of the mean (n= 6–10).
* Statistically signiﬁcant from zero time: P< 0.05.
@ Statistically signiﬁcant from the control group at the corresponding time: P< 0.05.
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Figure 1 Effect of meloxicam (1 and 2 mg/kg), octreotide (10 and 100 lg/kg) and their combination (meloxicam 1 mg/kg + octreotide
10 lg/kg) on arthritic rat paw oedema. The data represent the mean ± standard error of the mean (n= 6–10). *Statistically signiﬁcant
from control arthritic group at the corresponding time point: P< 0.05. Other signiﬁcances’ signs were omitted for simplicity.
Table 2 Effect of meloxicam, octreotide and their combination on the perception of thermal pain in hot plate test in rats.
Groups Reaction time (s)
Zero time 30 min 60 min 120 min
Control 8.30 ± 0.63 7.89 ± 0.93 9.56 ± 0.67 9.9 ± 0.60
Mel. 1 mg/kg 7.55 ± 0.79 15.26*,@ ± 2.26 12.53 ± 0.84 12.46 ± 1.43
Mel. 2 mg/kg 8.28 ± 0.78 16.41*,@ ± 0.94 16.64*,@ ± 2.82 17.10*,@ ± 1.96
Oct. 10 lg/kg 7.55 ± 0.79 7.77 ± 1.00 11.92 ± 1.16 12.93 ± 2.78
Oct. 100 lg/kg 8.20 ± 0.93 14.35 ± 0.60 16.64*,@ ± 1.70 16.55*,@ ± 1.20
Mel. 1 mg/kg + Oct. 10 lg/kg 8.06 ± 0.90 10.58 ± 1.90 13.76 ± 1.50 15.01*,@ ± 1.31
The data represents the mean ± standard error of the mean (n= 8).
* Statistically signiﬁcant from control arthritic group at the corresponding time point: P< 0.05.
@ Statistically signiﬁcant from zero time: P< 0.05.
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contractions) was counted for 30 min immediately after the
acetic acid injection and expressed as writhing numbers (Cha-
kraborty et al., 2004).
3.5. The plantar test
Animals were allowed to accommodate in 10 cm · 17 cm
enclosure of 7371-plantar test, Ugo Basile, Comerio, Italy.An infrared beam, (Halogen 64,607 OSRAM, 8 V-50 W-
IR movable bulb, Ugo Basile, Comerio, Italy) was applied
through the transparent surface of the enclosure to the plan-
tar surface of the right hind paw of each animal. Time re-
quired for the animal to withdraw its paw was recorded.
Pain threshold assessment was performed in the following
days: day 0 (before arthritic induction), 5, 9, 13, 17, 21,
25 and 29 (Kwon et al., 2002; Chillingworth and Donaldson,
2003).
Figure 2 Effect of meloxicam (1 and 2 mg/kg), octreotide (10 and 100 lg/kg) and their combination (meloxicam 1 mg/kg + octreotide
10 lg/kg) on acetic acid-induced writhing response in mice. The data represent the mean ± standard error of the mean (n= 6–10).
*Signiﬁcantly different from the control group P< 0.05. @Statistically signiﬁcant from combination (octreotide 10 lg/kg + meloxicam
1 mg/kg): P< 0.05.
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Figure 3 Effect of meloxicam, octreotide and their combination
on the perception of thermal pain in arthritic rats (plantar test).
The data represent the mean paw latency time ± standard error of
the mean of eight rats. *Statistically signiﬁcant from control
arthritic group at the corresponding time point: P< 0.05.
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One millilitre per hundred grams body weight of 44% yeast
suspension was administered by an intramuscular injection
into each animal of all the tested groups. Before yeast injection
rectal temperature was recorded for all groups. The rectal tem-
perature measured 18 h following the yeast injection serves as
the basic line of the elevated body temperature. Rectal temper-
ature was recorded by a multichannel electric thermometer
(TMP 812 Digital Thermometer, Ugo Basile, Comerio, Italy)
1 and 2 h after drugs’ administration (Roszkowski et al., 1971).
3.7. Evaluation of gastric ulcerogenic potential
Studies were performed in pyloric ligated rats (Shay et al.,
1945). Under ether anaesthesia a midline abdominal incision
was made. The pylorus was ligated, care being exercised that
neither damage to the blood supply nor traction on the pylorus
occurs. The test compounds were injected subcutaneously
immediately after pylorus ligation. After 4 h, the animals were
sacriﬁced, the abdomen was opened and a ligature was placed
around the oesophagus close to the diaphragm. The stomach
was removed, and the contents were drained in a centrifuge
tube. The mucosa was examined for mucosal necrotic lesions,
red streaks and red erosions and photos were taken with a dig-
ital camera. The total lesion number was counted as well as the
severity of lesions was calculated (Mo´zsik et al., 1982). The
volume of the gastric juice was carefully collected in graduated
tubes. After centrifugation the gastric acid output was deter-
mined by titration to pH 7.0 with 0.1 N NaOH and H+ output
was expressed as lEq/4 h (Isenberg, 1978). The gastric mucosa
was subjected to a histological examination.
After macroscopic evaluation of mucosal lesions, the stom-
achs were pinned ﬂat on cardboard and immersed in 10% for-
malin solution and later embedded in parafﬁn. Haematoxylin
and eosin sections were evaluated qualitatively under light
microscopy (Drury and Wallington, 1980).4. Statistical analysis
Values were expressed as means ± S.E. mean. Comparisons be-
tween means were carried out using different statistical tests
according to the nature of the determined parameter.Results of ul-
cer numbers and severitywere analysedusingKruskal–Wallis non-
parametric test followed by Dunn’s multiple comparisons test.
Data of carrageenan-induced rat paw oedema, adjuvant-in-
duced arthritis, hotplate test, plantar test, antipyretic effects
which involved measuring a repeated parameter on time inter-
vals, were analysed using repeated measures 2-way ANOVA
followed by Tukey HSD test for multiple comparisons. Results
of the experiments other than those mentioned were analysed
using one way ANOVA followed by Tukey HSD test for mul-
tiple comparisons.
Table 3 Effect of meloxicam, octreotide and their combination on yeast-induced hyperpyrexia in rats.
Group Rectal temperature (C)
Pre-yeast Pre-treatment Post-drug 60 min Post-drug 120 min
Control (hyperthermic rats) 37.20 ± 0.17 38.90* ± 0.13 39.08* ± 0.19 39.21* ± 0.16
Mel. 1 mg/kg 37.00 ± 0.12 38.80* ± 0.11 37.32@ ± 0.34 37.20@ ± 0.30
Mel. 2 mg/kg 37.12 ± 0.14 38.66* ± 0.18 37.40@ ± 0.22 37.13@ ± 1.02
Oct. 10 lg/kg 37.06 ± 0.25 38.60* ± 0.21 38.48* ± 0.25 39.11* ± 0.18
Oct. 100 lg/kg 37.57 ± 0.15 39.10* ± 0.14 38.23 ± 0.38 39.33* ± 0.26
Mel. 1 mg/kg + Oct. 10 lg/kg 36.80 ± 0.18 38.52* ± 0.17 37.30@ ± 0.15 38.25* ± 0.21
The data represents the mean ± standard error of the mean (n= 8).
* Statistically signiﬁcant from zero time: P< 0.05.
@ Statistically signiﬁcant from the hyperthermic control group at the corresponding time: P< 0.05.
Table 4 Effect of meloxicam, octreotide and their combination on the gastric mucosa in pylorus ligated rats using indomethacin as a
standard drug.
Parameters Groups
Normal Indomethacin
20 mg/kg
Meloxicam
1 mg/kg
Meloxicam
2 mg/kg
Octreotide
10l/kg
Octreotide
100l/kg
Meloxicam
1 mg/kg +
Octreotide
10 lg/kg
Number of lesions per rat – 15.00 ± 4.01*, 10.20* ± 4.46 14.20 ± 3.60*, – – 5.60 ± 1.24
Severity of lesions per rat – 29.70 ± 7.18*, 19.00* ± 4.98 26.40 ± 6.68*, – – 11.40 ± 2.10
Gastric acid volume (ml/4 h) 6.43 ± 0.48 8.35 ± 0.58 7.5 ± 0.65 7.65 ± 0.46 5.38 ± 0.58 7.20 ± 0.69 6.90 ± 0.61
Gastric acid output (lEq/4 h) 654.3 ± 74.1 1066.3 ± 107.8*, 981* ± 91.70 985.3 ± 97.90*, 642@47.50 562.8 ± 42.20@, 866.8 ± 22.31
The data represents the mean of 6–8 animals ± standard error of the mean.
* Statistically signiﬁcant from the normal group: P< 0.05.
@ Statistically signiﬁcant from ulcer induced indomethacin group: P< 0.05.
 Statistically signiﬁcant from combination (meloxicam 1 mg/kg + octreotide 10 lg/kg): P< 0.05.
Modulation of the pharmacological properties of meloxicam by octreotide in rats 127A probability level of less than 0.05 was accepted as being
signiﬁcant in all types of statistical tests. SPSS software (ver-
sion 10) was used to carry out all statistical tests except for
the 2-way ANOVA which was performed using Statistical soft-
ware, version 17.
5. Results
5.1. The carrageenan-induced rat paw oedema
Results are presented in Table 1. Pretreatment with meloxi-
cam signiﬁcantly decreased the carrageenan-induced oedema.
The inhibitory effect of 0.5, 1 and 2 mg/kg meloxicam was
35.7%, 42.9% and 46.4%, respectively, at the fourth hour.
Similarly, pretreatment with octreotide signiﬁcantly de-
creased the carrageenan-induced oedema. The inhibitory ef-
fect of 10, 25 and 100 lg/kg octreotide was 21.4%, 25%
and 32.1%, respectively, at the fourth hour. Pretreatment
with combinations of meloxicam 1 mg/kg and octreotide
10 lg/kg or meloxicam 1 mg/kg and octreotide 100 lg/kg
signiﬁcantly decreased the carrageenan-induced oedema with
an inhibitory effect of 42.9% at the fourth hour of the
experiment.
5.2. The adjuvant-induced arthritis
Results are graphically illustrated in Fig. 1.5.3. The hot plate test
Results are presented in Table 2. Meloxicam 1 mg/kg did not sig-
niﬁcantly increase the reaction time allover the experiment except
after 30 min of drug administration when compared to the control
group.However,meloxicam2 mg/kg showed a signiﬁcant increase
in the reaction time at 30, 60 and 120 min following drug adminis-
tration as compared with the control animals. Octreotide 100 lg/
kg resulted in a signiﬁcant increase in the reaction time after 60
and 120 min following drug administration.
5.4. The writhing test
Results are graphically illustrated in Fig. 2. Administration of
meloxicam (1 and 2 mg/kg), octreotide (10 and 100 lg/kg) or
their combination meloxicam (1 mg/kg) and octreotide
(10 lg/kg) before inducing writhing resulted in a signiﬁcant de-
crease in the number of writhes in mice.
5.5. The plantar test
Results are graphically illustrated in Fig. 3.
5.6. Antipyretic effects
There was a statistical signiﬁcant effect for meloxicam 1 and
2 mg/kg and the combination of meloxicam (1 mg/kg) and
Figure 5 A photomicrograph of the gastric mucosa after
indomethacin (20 mg/kg).
Figure 6 A photomicrograph of the gastric mucosa after admin-
istration of meloxicam (1 mg/kg) and meloxicam (2 mg/kg),
respectively.
128 S. Abdul Wanees El-Awdan et al.octreotide (10 lg/kg), where they produced a signiﬁcant de-
crease in the elevated body temperature reaching normal val-
ues when compared with those of the control group. Results
are presented in Table 3.
5.7. Evaluation of gastric ulcerogenic potential
Results are presented in Table 4. Meloxicam (1 and 2 mg/kg)
resulted in a number of lesions of 10.2 and 14.2 with a severity
of 19 and 26.4, respectively. In addition, acid output was in-
creased by 50% and 50.5%, respectively, as compared to that
of the pyloric ligated normal group. Octreotide (10 and 100 lg/
kg) did not cause lesions and did not signiﬁcantly affect the
normal gastric volume. Acid output was not signiﬁcantly chan-
ged from the normal group. Treatment of the rats with the
combination of meloxicam (1 mg/kg) and octreotide (10 lg/
kg) resulted in normal gastric acid volume and normal acid
output. Results are presented in Table 4.
5.8. Histological examination of the gastric mucosa
The normal picture of the gastric mucosa was demonstrated
after examination of sections obtained from the normal group
receiving saline (Fig. 4). Gastric mucosa of rats which received
indomethacin was highly affected showing a big area of ulcer-
ation occupying about two-thirds of the thickness of the muco-
sa (Fig. 5). The tissue architecture is more or less preserved.
Gastric mucosa of rats that received meloxicam 1 mg/kg
showed that the normal architecture of the glands is distorted
with the presence of many dilated blood vessels in between the
muscle ﬁbres of the muscularis mucosa, which is thickened.
Lymphocytic inﬁltration is seen in the muscularis mucosa
and in the bases of the glands (Fig. 6). Gastric mucosa of rats
that received meloxicam 2 mg/kg showed some deformities of
the pits of the glands with abnormally dilated blood vessels
in between and at the bases of the pits (Fig. 7).
Gastric mucosa of rats injected with octreotide 10 lg/kg
shows more or less normal architecture of the gastric glands.
Slight lymphocytic inﬁltration is seen in the lamina propria be-
tween the bases of the glands (Fig. 8). Gastric mucosa of rats
injected with octreotide 100 lg/kg showed that the structural
architecture is still preserved, although there are unstained
areas in the lumen of the glands due to necrosis and degener-
ation of many cells in the glands (Fig. 9).
Gastric mucosa of rats injected with a combination of
octreotide 10 lg/kg and meloxicam 1 mg/kg shows nearlyFigure 4 A photomicrograph of the gastric mucosa of the
control rat.normal architecture of the mucosal glands in spite of the pres-
ence of oedema in the necks of some glands. Area of conges-
tion is seen at the base of the glands with thickening of the
muscularis mucosa (Fig. 10).
6. Discussion
The carrageenan-induced rat paw oedema in the present exper-
iments revealed visible redness and pronounced swelling that
were well developed by 4 h. The same ﬁnding was observed
by other authors (Panda and Chowdary, 2008; Li et al.,
2003). Currently, meloxicam showed signiﬁcant anti-inﬂam-
matory effect. These results are in agreement with those of
many studies showing the anti-inﬂammatory effect of meloxi-
cam (Engelhardt et al., 1995; Corbett et al., 2010). The anti-
inﬂammatory effect of meloxicam was evident starting from
the ﬁrst hour of carrageenan-induced oedema, suggesting
interference with the inﬂammatory mediators implicated in
Figure 7 A photomicrograph of the gastric mucosa after admin-
istration of meloxicam (1 mg/kg) and meloxicam (2 mg/kg),
respectively.
Figure 8 A photomicrograph of the gastric mucosa after
administration of octreotide (10 lg/kg) and octreotide (100 lg/kg).
Figure 9 A photomicrograph of the gastric mucosa after
administration of octreotide (10 lg/kg) and octreotide (100 lg/kg).
Figure 10 A photomicrograph of the gastric mucosa after
meloxicam (1 mg/kg) + octreotide (10 lg/kg) adminstration.
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anti-inﬂammatory effect of meloxicam indicates its extended
effect in the late phase of carrageenan-induced oedema, hence,
affecting further release of prostaglandins as well as the pro-duction of neutrophil-derived free radicals such as hydrogen
peroxide, superoxide and other neutrophil derived mediators
(Peskar et al., 1991; Warner et al., 1999).
Octreotide administered 1 h before the injection of carra-
geenan inhibited formation of oedema. The effect started after
the ﬁrst hour and persisted till the fourth hour. The acute anti-
inﬂammatory effect of octreotide elicited in the present study is
in accordance with what was observed by many authors (Hep-
pelmann and Pawlak, 1997; Kurnatowska and Pawlikowski,
2001; Imhof et al., 2011).
It has been suggested that somatostatin may act as an anti-
inﬂammatory agent by inhibiting plasma and leukocyte extrav-
asation. Somatostatin acts antagonistically to substance P, the
main neuroendocrine proinﬂammatory mediator (Ten Bokum
et al., 2000). It induces vasoconstriction and inhibits angiogen-
esis (Szolcsa´nyi et al., 1998).
Combinations of meloxicam and octreotide in the present
study signiﬁcantly decreased the carrageenan-induced oedema
in a similar way like that of each of them alone. It is worth
pointing out that using the combination of the drugs in acute
experiments produced similar effects like using the single
drugs.
Results of the present study revealed that oedema was pro-
duced in Freund’s-induced inﬂammation (Donaldson et al.,
1993). The biphasic nature of the disease is particularly pro-
nounced in the rat polyarthritis model (Calvino et al., 1987).
As a preferential COX-2 inhibitor, the signiﬁcant decrease of
130 S. Abdul Wanees El-Awdan et al.the paw oedema formed in Freund’s adjuvant-induced arthritis
by meloxicam was in accordance with results of many
researchers (Engelhardt et al., 1995; Agha et al., 1999; Tsubou-
chi et al., 2000).
Octreotide in the present study signiﬁcantly decreased the
inﬂammatory response in the paw oedema volume in rats starting
from day 15 till the end of the experiment. Octreotide results were
consistent with the data concluded by others (Kurnatowska and
Pawlikowski, 2000). The authors examined the effect of somato-
statin analogue octreotide on the adjuvant arthritis in rats. It was
suggested that somatostatindown-modulates anumberof immune
functions such as lymphocytes proliferation, immunoglobulin pro-
duction and the release of the proinﬂammatory cytokines such as
interferon-c (INF-c) (Ten Bokum et al., 2000), which may aid in
the anti-inﬂammatory effect in chronic models like arthritis. Fur-
thermore, the inhibition of plasma and leukocyte extravasation
(Wiedermann et al., 1993), inhibition of inﬂammation promoting
factors such as substance P (Lotz et al., 1987) and the decreased
proliferation of synovial cells (TannenbaumandPatel, 1986) could
be other possible mechanisms by which somatostatin and its ana-
logues exert the anti-inﬂammatory effect in chronic inﬂammatory
models.
One way in which somatostatin may reduce arthritic symp-
toms through peripheral mechanisms is through the inhibition
of inﬂammation promoting factors such as substance P (Lotz
et al., 1987). Furthermore, it has been pointed out that
somatostatin has been shown to inhibit immunoglobulin pro-
duction by B lymphocytes and proliferation of human T lym-
phocytes (Levine et al., 1984).
The current study indicated that meloxicam octreotide have
both peripheral and central analgesic properties. The hot plate
test has been used by many investigators and has been found
to be suitable for evaluation of centrally but not peripherally
acting analgesics (Woolfe and McDonald, 1944). In order to
distinguish between the central and peripheral analgesic ac-
tions of the tested drugs, their peripheral analgesic activity
was investigated by their inhibitory effects on chemical-in-
duced nociceptive stimuli (Zakaria et al., 2001).
Both meloxicam and octreotide may exert an analgesic effect
probably by inhibiting synthesis or action of prostaglandins.
Results of meloxicam in the writhing test of mice are in accor-
dance with what other studies revealed (Warner and Mitchell,
2004). Inhibition of prostaglandin synthesis in the CNS appears
to be a property of all NSAIDs (Cain et al., 1997).
Results of the present experiments indicated that meloxi-
cam, octreotide as well as their combination produced a signif-
icant rise in the time required for the rats to respond to the
thermal stimulation. These results are in accordance with those
of other authors who investigated the analgesic effects of both
meloxicam (Engelhardt et al., 1995) and octreotide (Sebastian
and Belchetz, 1990). The suggested mode of the antinociceptive
action of NSAIDs was considered to be related to their anti-
inﬂammatory action and was thought to be due to the inhibi-
tion of prostaglandin production at the site of inﬂammation
(Ferreira, 1979). The analgesic effect of octreotide shown as
inhibition of nociceptive stimuli can be explained on the basis
of blocking the release of substance P (Lembeck et al., 1982).
The present results showed that meloxicam produced a de-
crease in the elevated body temperature. However no effect
was produced by octreotide 10 or 100 lg/kg. The major mech-
anism of antipyretics involves lowering PGE2 by directly inhib-
iting COX activity (Flower and Vane, 1972).In the pyloric ligated rats in the current study, it has been
shown that indomethacin signiﬁcantly resulted in a lesion num-
ber with a high severity. Furthermore, a signiﬁcant increase in
the acid output compared to that of the pyloric ligated normal
groupwas produced. These results are consistent with other pre-
vious experiments (Halici et al., 2005). Anti-inﬂammatory
agents such as indomethacin reduce gastric cyclooxygenase
activity, decrease endogenous prostaglandin levels (Konturek
et al., 1984) and increase acid secretion (Sairam et al., 2002). Re-
sults of the present study showed that meloxicam induced le-
sions in rats and signiﬁcantly increased acid output as
compared to that of the pyloric ligated normal group indicating
that it could induce gastrointestinal lesions. These results lie on
line with previous reports (Villegas et al., 2001) but such results
did not fully support other reported results that showed that
meloxicam is superior to conventional NSAIDs in terms of its
anti-inﬂammatory potency and showed particularly good gas-
tric tolerance (Engelhardt et al., 1995).
Meloxicam has demonstrated a preferential inhibition for
COX-2 in a large number of biological assay models. Never-
theless, this selectivity is not free of toxic effects on gastric mu-
cosa, and the use of it is still associated with gastrointestinal
side effects (McKenna, 1999). In low doses, meloxicam may
be safer than other NSAIDs, but its toxicity proﬁle may not
be much better than that of non-selective COX inhibitors
(Churchill et al., 1996).
In the present study, octreotide caused no lesions and signiﬁ-
cantly lowered the acid output in the stomach indicating that this
effect could be involved in its gastroprotection.More interestingly,
treatmentof the ratswith the combinationofmeloxicamandoctre-
otide resulted in normal gastric acid volume and normal acid out-
put. Somatostatin downregulates exocrine secretion of pancreatic
enzymes and gastric acid (Schusdziarra, 1996) which may explain
its gastroprotective effect.Thedecrease in acidity inpylorus-ligated
rats suggests that an anti-secretory action occurred and may ex-
plain how somatostatin works.
In rats with ulcer, the gastrin level in the plasma, gastric
juice and the mucosal tissue increase, while the somatostatin
level declines (Sun et al., 2002). The combination of the anti-
inﬂammatory drug (meloxicam) and gastroprotective effect
of the somatostatin analogue (octreotide) is favourable when
taken to account the serious limitations of a large number of
anti-inﬂammatory agents that show a tendency to produce gas-
tric irritation, bleeding and mucosal cellular damage (Lanza,
1984, Nassar et al., 2011).
Summing up, the data presented above indicate that the
octreotide possesses anti-inﬂammatory, analgesic effects to-
gether with a favourable gastrointestinal proﬁle. Octreotide
is proposed as a lead molecule for a new class of anti-inﬂam-
matory and analgesic agents especially with patients suffering
from other chronic diseases and already taking octreotide as
a drug. The search for other somatostatin analogues exhibiting
higher effects is needed since they represent a new promising
group of anti-inﬂammatory drugs.References
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